VATE

Innovate Corp. (VATE) | Rumor.io

Innovate

VATE

Attention (50-day avg)0%

Attention rank (50-day avg)#2,659

Bullish sentiment (50-day avg)85%

Price to earnings ratio-1.53

Market capitalization100.9M

Earnings per share-1.79

Dividend yield (TTM)9.62%

Revenue (annual)1.2B

Net income (annual)-64M

Social

What share of all stock conversation is about VATE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 10

INNOVATE Corp. (VATE) filed a Form 424B5 prospectus supplement to initiate an "at-the-market" equity offering, which may sell shares through Jefferies.
The company's tangible book value is negative $393M, and it has short-term debt of $554M with cash of $88M.
The sale of DBM Global to IES Holdings for approximately $650 million may be a positive for the company, but it is currently down after the news, despite being over 4x the current market cap.

Generated by AI

Sentiment

Of the messages about VATE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.72% +0.74
Bearish	—	—	—	12.28% -0.74

Bullish· Aug 7

Innovate Corp. has reported Q2 2026 revenue up 74% YoY to $421.6 million, swinging to $10.4 million net income.
The stock has a low float, which, combined with double-digit margin, is contributing to its significant price movement.
The stock is considered a real squeeze/momentum candidate, with a small public float, rapidly improving EBITDA/backlog, and a major positive earnings surprise, making it a potential candidate for a short squeeze.

Bearish· Jan 21

The company's huge pump and dump scheme is expected to end with a massive drop in value.
The asset's massive increase in value is likely due to a shelf offering that is waiting to be dropped, which could lead to dilution and a decrease in value.
The asset's price increase is not justified by the news, and the company may be intentionally driving up the price to dump on retail investors.

Generated by AI

Topics

Of the messages about VATE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	90.48%
Technical Analysis	—	0%	0%	3.06%
Earnings	—	0%	0%	1.36%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	5.1%

Earnings· Mar 2

INNOVATE Corp. ($VATE) has announced a date change for its fourth quarter and full year 2022 earnings call.
The new date has not been specified, but the company will provide further information at a later time.
The earnings call is a key event for investors to receive updates on the company's financial performance and future prospects.

Announcements· Jan 21

INNOVATE Corp. ($VATE) announced FDA approval of MediBeacon's TGFR System for accurate kidney function testing.
The system measures kidney function by tracking a fluorescent tracer agent's clearance rate through a skin sensor, providing real-time readings at the point of care.
Clinical trials demonstrated strong efficacy with a P30 value of 94%, meeting FDA requirements, and the technology works effectively across the adult population regardless of age, weight, sex, gender, race, or ethnicity.

Generated by AI

Community

Of the messages about VATE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	3.49%
Newcomers	—	0%	0%	96.51%

Regulars· Jan 21

$VATE's stock surged 104% today, with the alert being timely from when it was first sent over an hour ago.
The FDA has approved the MediBeacon Transdermal GFR for assessing kidney function in patients with normal or impaired renal function.
VATE's stock increased by 45.4% pre-market, driven by the FDA approval of the MediBeacon Transdermal GFR.

Newcomers· Aug 10

INNOVATE Corp.'s (VATE) recent filing of a 424B5 prospectus supplement has triggered an "at-the-market" equity offering, allowing the company to sell shares through Jefferies.
The company's debt situation remains a concern, with a negative tangible book value of $393M and short-term debt of $554M, despite having $88M in cash.
The acquisition of DBM Global by IES Holdings for $650M has raised questions about INNOVATE Corp.'s decision to sell its best asset, with some investors wondering if the company is trying to protect itself with a poison pill.

Generated by AI

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE CORP.® (NYSE: VATE) (“INNOVATE” or the “Company”) announced today the successful closing of the previously announced transaction between INNOVATE and CONX Corp. (“CONX”), pursuant to which CONX acquired a controlling interest in HC2 Broadcasting Holdings Inc. (“HC2”), a holding company for INNOVATE’s Broadcasting segment. The transaction follows the completion of the Broadcasting segment’s refinancing announced on June 1, 2026. CONX has acqui

28d agoYahoo Finance

Could IES Holdings (IESC) Win Big While INNOVATE (VATE) Bets its Future on Debt Reduction?

On August 10, IES Holdings, Inc. (NASDAQ:IESC) announced a definitive agreement to acquire DBM Global from INNOVATE Corp. (NYSE:VATE) for approximately $650 million in combined cash and stock ($685 million total consideration including minority interest buyouts and tax election payments). This major structural deal reshapes both companies, but their underlying financial trajectories explain why the […]

1mo agoYahoo! Finance Canada

VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge

Detailed price information for Innovate Corp (VATE-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Innovate: This Is Not What I Expected At All; I Reiterate My Sell Rating (NYSE:VATE)

1mo agoSeeking Alpha

IES to Acquire DBM Global From Innovate for $650 Million

1mo agoYahoo Finance

Also Discussed

Investors talking about VATE also mention

#	Name	Attention
1	Werewolf Therapeutics Inc.HOWL	0%0
2	Creative Medical Technology Holdings, Inc.CELZ	0%0
3	GMGI - Golden Matrix Group, Inc.	——
4	GT Biopharma Inc.GTBP	0%0
5	KMPH - KemPharm, Inc.	——
6	Trevi Therapeutics, Inc.TRVI	0%new
7	MDVL - MedAvail Holdings, Inc.	——
8	GRIL - Muscle Maker, Inc.	——
9	GLDN - Nicholas Gold Income ETF	——
10	DYNT - Dynatronics Corporation	——

Innovate Corp.

Industrials
Engineering & Construction

Innovate Corp. is a diversified holding company that primarily focuses on owning, operating, and investing in industrial services and financial services sectors. Its principal function is to acquire and manage a portfolio of subsidiary companies across various industries, thus providing operational efficiencies and strategic growth opportunities. Notable features of Innovate Corp. include its operations in engineering, construction, and maintenance projects, which serve critical sectors such as infrastructure and energy. Beyond the industrial scope, Innovate Corp. engages in insurance and asset management through its financial services segment, offering solutions to both business and individual clients. The company plays a significant role in creating synergies between its diverse operations, leveraging its broad industry expertise to enhance value creation across its portfolio. Through strategic acquisitions and innovative management practices, Innovate Corp. aims to capitalize on emerging market trends and sustain its position as a pivotal player in the sectors it operates within. As such, it stands as a versatile entity in the financial market, impacting industrial growth and financial solutions.

Website

Location

295 Madison Avenue

New York, NY, 10017

United States

Social

What share of all stock conversation is about VATE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 10

INNOVATE Corp. (VATE) filed a Form 424B5 prospectus supplement to initiate an "at-the-market" equity offering, which may sell shares through Jefferies.
The company's tangible book value is negative $393M, and it has short-term debt of $554M with cash of $88M.
The sale of DBM Global to IES Holdings for approximately $650 million may be a positive for the company, but it is currently down after the news, despite being over 4x the current market cap.

Generated by AI

Sentiment

Of the messages about VATE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.72% +0.74
Bearish	—	—	—	12.28% -0.74

Bullish· Aug 7

Innovate Corp. has reported Q2 2026 revenue up 74% YoY to $421.6 million, swinging to $10.4 million net income.
The stock has a low float, which, combined with double-digit margin, is contributing to its significant price movement.
The stock is considered a real squeeze/momentum candidate, with a small public float, rapidly improving EBITDA/backlog, and a major positive earnings surprise, making it a potential candidate for a short squeeze.

Bearish· Jan 21

The company's huge pump and dump scheme is expected to end with a massive drop in value.
The asset's massive increase in value is likely due to a shelf offering that is waiting to be dropped, which could lead to dilution and a decrease in value.
The asset's price increase is not justified by the news, and the company may be intentionally driving up the price to dump on retail investors.

Generated by AI

Topics

Of the messages about VATE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	90.48%
Technical Analysis	—	0%	0%	3.06%
Earnings	—	0%	0%	1.36%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	5.1%

Earnings· Mar 2

INNOVATE Corp. ($VATE) has announced a date change for its fourth quarter and full year 2022 earnings call.
The new date has not been specified, but the company will provide further information at a later time.
The earnings call is a key event for investors to receive updates on the company's financial performance and future prospects.

Announcements· Jan 21

INNOVATE Corp. ($VATE) announced FDA approval of MediBeacon's TGFR System for accurate kidney function testing.
The system measures kidney function by tracking a fluorescent tracer agent's clearance rate through a skin sensor, providing real-time readings at the point of care.
Clinical trials demonstrated strong efficacy with a P30 value of 94%, meeting FDA requirements, and the technology works effectively across the adult population regardless of age, weight, sex, gender, race, or ethnicity.

Generated by AI

Community

Of the messages about VATE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	3.49%
Newcomers	—	0%	0%	96.51%

Regulars· Jan 21

$VATE's stock surged 104% today, with the alert being timely from when it was first sent over an hour ago.
The FDA has approved the MediBeacon Transdermal GFR for assessing kidney function in patients with normal or impaired renal function.
VATE's stock increased by 45.4% pre-market, driven by the FDA approval of the MediBeacon Transdermal GFR.

Newcomers· Aug 10

INNOVATE Corp.'s (VATE) recent filing of a 424B5 prospectus supplement has triggered an "at-the-market" equity offering, allowing the company to sell shares through Jefferies.
The company's debt situation remains a concern, with a negative tangible book value of $393M and short-term debt of $554M, despite having $88M in cash.
The acquisition of DBM Global by IES Holdings for $650M has raised questions about INNOVATE Corp.'s decision to sell its best asset, with some investors wondering if the company is trying to protect itself with a poison pill.

Generated by AI

Innovate

Social

Aug 10

Bullish· Aug 7

Bearish· Jan 21

Earnings· Mar 2

Announcements· Jan 21

Regulars· Jan 21

Newcomers· Aug 10

Innovate Corp completes sale of broadcasting unit to CONX

INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX

Could IES Holdings (IESC) Win Big While INNOVATE (VATE) Bets its Future on Debt Reduction?

VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge

Innovate: This Is Not What I Expected At All; I Reiterate My Sell Rating (NYSE:VATE)

IES to Acquire DBM Global From Innovate for $650 Million

Also Discussed

Innovate Corp.

Company Information

Location

Social

Aug 10

Bullish· Aug 7

Bearish· Jan 21

Earnings· Mar 2

Announcements· Jan 21

Regulars· Jan 21

Newcomers· Aug 10

Innovate Corp completes sale of broadcasting unit to CONX

INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX

Could IES Holdings (IESC) Win Big While INNOVATE (VATE) Bets its Future on Debt Reduction?

VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge

Innovate: This Is Not What I Expected At All; I Reiterate My Sell Rating (NYSE:VATE)

IES to Acquire DBM Global From Innovate for $650 Million

Also Discussed